Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06215118 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
A Phase 1 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT06215118: Recruiting Phase 1 study of Multiple Myeloma, sponsored by Pfizer.
NCT06215118 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 87 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06215118, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement. All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle. Participants will receive study medicine until: * their disease progresses or, * they experience unacceptable side effects or, * they choose to no longer take part in the study. The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.
Primary Outcome
Dose limiting toxicity rate based on dose limiting toxicity evaluable participants
Conditions Studied
Interventions
- DRUG Elranatamab
- DRUG Iberdomide
Study Locations (20)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute - Chestnut Hill - Newton
- University of Massachusetts Chan Medical School - Worcester
- University of Massachusetts Chan Medical School - Worcester
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
- Winship Cancer Institute - Atlanta
Indiana
- Indiana CTSI Clinical Research Center (ICRC) - Indianapolis
- Indiana University Health University Hospital - Indianapolis
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC) - Indianapolis
Nebraska
- Methodist Hospital - Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer - Methodist - Omaha
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists - Omaha
New Jersey
- MSK Basking Ridge - Basking Ridge
- MSK Monmouth - Middletown
- MSK Bergen - Montvale
Maryland
- University of Maryland - Baltimore
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2028-03-09 |
| Phase | Phase 1 |
What NCT06215118 shows while recruiting
NCT06215118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Elranatamab is the first listed.
NCT06215118 names 20 study sites across 7 states, led by Massachusetts, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT06215118 about?
NCT06215118 is a clinical study titled "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)". The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination th...
What is the current status of trial NCT06215118?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2024-02-20. Estimated completion is 2028-03-09.
What conditions does trial NCT06215118 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06215118?
The interventions under investigation include: Elranatamab (DRUG), Iberdomide (DRUG).
Who is sponsoring clinical trial NCT06215118?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06215118 being conducted?
This trial has 20 study locations across Georgia, Indiana, Maryland, Massachusetts, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06215118's enrollment target sits among peer trials
87 191st of 438 higher than 248 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI